ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Extension Study of Vebicorvir for Chronic HBV Does Not Achieve Meaningful SVR Rates
November 16, 2020Assembly Biosciences provided an update on the ongoing open-label Phase 2 extension study (Study 211) of vebicorvir (VBR, or ABI-H0731) in patients with chronic HBV infection. Study 211 is exploring whether sustained virologic response (SVR) could be ... -
USPSTF Advises Broader Age Range for Hep C Screening
August 28, 2019The U.S. Preventive Services Task Force recommends hepatitis C virus (HCV) infection screening for individuals aged 18 to 79 years.
Pharma Sources Insight January 2025
